GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody
30 Agosto 2022 - 06:07PM
Business Wire
- The first publication confirms the neurotoxic role of
HERV-K/HML-2 ENV detected in the cerebrospinal fluid of sporadic
ALS patients and the preclinical therapeutic effect of GeNeuro’s
anti-HERV-K ENV antibody in neutralizing HERV-K/HML-2 ENV
toxicity.
- The second publication provides a clinically based rationale
for the therapeutic use of a specific neutralizing antibody
addressing sporadic ALS neuropathology, by demonstrating the
positive role of HERV-K ENV-specific but low-abundant natural
autoantibodies on the duration of patients’ survival.
- Sporadic ALS is a devastating disease affecting 10,000 new
patients per year in the U.S. and Europe, with a very limited
survival prognosis.
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a
biopharmaceutical company developing new treatments for
neurodegenerative and autoimmune diseases such as multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe
consequences of COVID-19 (post-COVID), announced today the joint
publications in the leading scientific journal "Annals of
Neurology" of the results of the collaboration between GeNeuro and
the National Institute of Neurological Disorders and Stroke
(NINDS). NINDS is part of the National Institutes of Health (NIH)
of the United States. The two publications describe the novel
pathogenic mechanism of HERV-K in sporadic ALS and confirm the
rationale for the therapeutic relevance of GeNeuro's antibody to
neutralize this neurotoxic protein.
Annals of Neurology is an official journal of the American
Neurological Association. The online publications and their hard
copy version in the last issue of the journal (HERV-K envelope in
spinal fluid of Amyotrophic Lateral Sclerosis is toxic - Steiner et
al, & Antibody response to HML-2 may be protective in
Amyotrophic Lateral Sclerosis - Garcia-Montojo et al. - Annals of
Neurology) present preclinical data showing that HERV-K/HML-2
Envelope protein (HERV-K ENV) is present in the cerebrospinal fluid
(CSF) of sporadic ALS patients, leads to neuronal cell injury and
death, and targets a now identified cellular receptor. The
studies also show that the neurotoxic properties of the HERV-K ENV
protein from ALS patients’ CSF are neutralized by GeNeuro’s
anti-HERV-K ENV antibody and that, in patients with sporadic ALS,
higher levels of autoantibodies targeting the HERV-K ENV protein
are associated with a longer survival.
Click here to read the full press release
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It owns rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220830005784/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap Louis-Victor Delouvrier / Mathilde Bohin
(investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33 1 44 71 94
98 geneuro@newcap.eu
Grafico Azioni GeNeuro (EU:GNRO)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni GeNeuro (EU:GNRO)
Storico
Da Mar 2023 a Mar 2024